Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
3.050
-0.180 (-5.57%)
Dec 20, 2024, 4:00 PM EST - Market closed
Aprea Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Aprea Therapeutics stock have an average target of 15.5, with a low estimate of 11 and a high estimate of 20. The average target predicts an increase of 408.20% from the current stock price of 3.05.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for APRE stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +555.74% | Dec 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +555.74% | Nov 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +555.74% | Oct 24, 2024 |
| Wedbush | Wedbush | Buy Reiterates $11 | Buy | Reiterates | $11 | +260.66% | Aug 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +555.74% | Aug 12, 2024 |
Financial Forecast
Revenue This Year
1.37M
from 583.23K
Increased by 134.21%
Revenue Next Year
612.00K
from 1.37M
Decreased by -55.20%
EPS This Year
-2.60
from -3.95
EPS Next Year
-1.52
from -2.60
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 1.9M | 1.9M | 1.9M | |||
| Avg | 1.4M | 612,000 | 612,000 | |||
| Low | 900,620 | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 224.1% | 38.4% | 208.8% | |||
| Avg | 134.2% | -55.2% | - | |||
| Low | 54.4% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.51 | -1.00 | -0.90 | ||
| Avg | -2.60 | -1.52 | -1.68 | ||
| Low | -2.65 | -2.50 | -2.56 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.